Abstract:
The present invention relates to a method for biologically producing, from seaweeds, 3,6-anhydro-L-galactitol (L-AHGol) which is a novel sugar alcohol, and agarobititol (ABol) which is in a disaccharide form having 3,6-anhydro-L-galactitol (L-AHGol) as a reducing end, by using a genetic engineering technique in GRAS strains.
Abstract:
The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.
Abstract:
The present invention relates to a use of an agarobiose or agarooligosaccharides having anticariogenic activity. More specifically, a lower concentration of agarobiose or agarooligosaccharides than the concentration of xylitol suppresses the growth of Streptococcus mutans and suppresses acid production, and thus can be used for anti-cariogenic purposes.
Abstract:
The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.
Abstract:
The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.
Abstract:
The present invention relates to a heat-resistant agarase and a monosaccharide production method using same. More particularly, in the present invention, a heat-resistant agarase may be used to produce galactose and 3,6-anhydro-L-galactose at high yield by efficiently breaking down agarose or agar without a chemical pretreatment, a neutralization process, or an agarotriose hydrolase treatment process.
Abstract:
The present invention relates to a use of 3,6-anhydro-L-galactose for preventing dental caries. More specifically, 3,6-anhydro-L-galactose inhibits the growth of oral microorganisms and exhibits anti-caries activity to inhibit the production of acids caused by the consumption of a carbon source by the oral microorganisms. Thus, 3,6-anhydro-L-galactose can be used in pharmaceuticals, food products, oral hygiene preparations, etc. for preventing, ameliorating or treating oral diseases caused by oral microorganisms, such as dental caries, gingivitis, periodontitis, oral mucosal ulcer, halitosis or xerostomia.
Abstract:
The present invention relates to a recombinant microorganism metabolizing 3,6-anhydro-L-galactose and a use thereof, and, more particularly, can produce ethanol from a recombinant microorganism expressing an enzyme group involved in a metabolic pathway of 3,6-AHG.
Abstract:
The present invention relates to a recombinant microorganism metabolizing 3,6-anhydro-L-galactose and a use thereof, and, more particularly, can produce ethanol from a recombinant microorganism expressing an enzyme group involved in a metabolic pathway of 3,6-AHG.